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Background: It is not clear if sentinel lymph node (SLN) mapping can improve outcomes in patients with
colorectal cancers. The purpose of this study was to determine the prognostic values of ex vivo sentinel lymph
node (SLN) mapping and immunohistochemical (IHC) detection of SLN micrometastasis in colorectal cancers.
Methods: Colorectal cancer specimens were obtained during radical resections and the SLN was identified by
injecting a 1% isosulfan blue solution submucosally and circumferentially around the tumor within 30 min after
surgery. The first node to stain blue was defined as the SLN. SLNs negative by hematoxylin and eosin (HE) staining
were further examined for micrometastasis using cytokeratin IHC.
Results: A total of 54 patients between 25 and 82 years of age were enrolled, including 32 males and 22 females.
More than 70% of patients were T3 or above, about 86% of patients were stage II or III, and approximately 90% of
patients had lesions grade II or above. Sentinel lymph nodes were detected in all 54 patients. There were 32
patients in whom no lymph node micrometastasis were detected by HE staining and 22 patients with positive
lymph nodes micrometastasis detected by HE staining in non-SLNs. In contrast only 7 SLNs stained positive with
HE. Using HE examination as the standard, the sensitivity, non-detection rate, and accuracy rate of SLN
micrometastasis detection were 31.8% (7/22), 68.2% (15/22), and 72.2%, respectively. Micrometastasis were identified
by ICH in 4 of the 32 patients with HE-negative stained lymph nodes, resulting in an upstaging rate 12.5% (4/32).
The 4 patients who were upstaged consisted of 2 stage I patients and 2 stage II patients who were upstaged to
stage III. Those without lymph node metastasis by HE staining who were upstaged by IHC detection of
micrometastasis had a significantly poorer disease-free survival (p = 0.001) and overall survival (p = 0.004).
Conclusion: Ex vivo localization and immunohistochemical detection of sentinel lymph node micrometastasis in
patients with colorectal cancer can upgrade tumor staging, and may become a factor affecting prognosis and
guiding treatment.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1350200526694475.
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Colorectal cancer is the most common malignancy in men
and women, and the fourth leading cause of cancer-related
death worldwide [1]. The status of lymph nodes in colo-
rectal carcinoma is the most important prognostic factor
for recurrence and overall survival (OS), and also largely
determines whether adjuvant chemotherapy should be
given [2]. Approximately 70-90% of patients with no
lymph node involvement will survive 5 years, whereas only
40% of those with lymph node metastases will survive for
that length of time. However, about 30% of patients with
node-negative colon cancer staged by standard pathologic
techniques experience recurrent locoregional or distant
metastases within 5 years [1,2]. One of the possible rea-
sons for the variations in outcome among patients with
node-negative disease is that there is inaccurate or incom-
plete nodal staging [3].
All lymph nodes within resected specimens should be
examined after surgery to obtain an accurate N stage; how-
ever, small lymph nodes with metastases are likely to be
missed during conventional gross pathological examin-
ation. Study has shown that> 70% of the positive lymph
nodes are< 2 mm [4]. The benchmark of 12 as a mini-
mum acceptable number of lymph nodes obtained during
colorectal cancer resection has been adopted as a quality
measure for surgical practice by many organizations. Even
so, two large population-based studies found that only 37-
49% of patients with colon cancer receive an adequate
lymph node evaluation [5-7]. Techniques such as fat clear-
ance are used to increase the yield of lymph nodes, but
these methods are time-consuming and not used routinely.
Several studies have reported nodal micrometastasis in
colorectal cancer by examination methods such as serial
sectioning, immunohistochemistry (IHC), or reverse
transcriptase-polymerase chain reaction (RT-PCR). How-
ever, it is not clear if these findings indicate a worse prog-
nosis [5,8-11]. In addition, these ultrastaging techniques
are too costly and time-consuming for use on the 12 or
more lymph nodes in every colorectal cancer specimen.
The sentinel node (SLN) is the first lymph node to re-
ceive lymphatic drainage from a tumor. In concept, the
SLN has the highest chance of harboring tumor cells be-
cause they directly drain from the tumor. The concept of
SLN allows focused examination on just a few nodes at
greatest risk for metastatic involvement. If lymph node sta-
ging can be upgraded by focusing on detection of a few
SLNs using conventional and immunohistochemical tech-
niques, better clinical outcomes may be expected. With
successful application of SLN detection technique in breast
cancer [12-14], investigators have attempted to apply this
technique in colorectal cancer. Many studies have demon-
strated the feasibility of applying SLN detection techniques
in colorectal cancer; however, the detection rate, sensitivity,
and false negative rate vary considerably [1,3,4,15-26].Moreover, as yet only a few studies have shown that sur-
vival of colorectal cancer patients can be influenced by the
application of the SLN technique [18,19,27].
The purpose of this study was to determine the prognos-
tic value of ex vivo sentinel lymph node (SLN) mapping
and immunohistochemical detection of SLN micrometas-
tasis in colorectal cancers.
Materials and methods
Patients
A total of 54 patients with surgery-naive colorectal cancers
who received radical operations at the Department of Ab-
dominal Surgery, Sun Yat-sen University Cancer Center
between March and October of 2003 were included in this
study. All patients had proven colorectal adenocarcinoma
by preoperative pathological biopsy examination, and all
received clinical examination, chest X-ray, abdominal ultra-
sound, colonoscopy, and thoracoabdominal computed
tomography (CT) scans. Patients with multiple primary
colorectal tumors, tumor local excision, severe local infil-
tration, surgery in tumor lymphatic drainage areas, emer-
gency operations, non-en bloc resections, and M1 patients
preoperatively or intraoperatively were excluded from this
study. Informed consent was obtained from all patients,
and this study was approved by the Institutional Review
Board of our hospital.
SLN mapping
Enrolled patients received standard radical operations
per conventional procedures after routine preoperative
preparations. SLN localization was performed on ex vivo
specimens within 30 minutes or resection using 1% iso-
sulfan blue solution (Sigma-Aldrich USA). The specimen
was opened at the anti-mesenteric border and 0.5-2 ml
(depending on the volume of the tumor) 1% isosulfan
blue solution was injected submucosally and circumfer-
entially around the tumor. The injection sites were then
gently massaged for 5 minutes to push the tracer into
the lymphatic vessels. The first node to stain blue was
defined as the SLN.
Pathologic examination
The SLNs were excised and processed separately. There-
after, a minimum of 12 non-SLNs as recommended by the
UICC/AJCC guidelines were dissected from the specimen.
All lymph nodes were collected by the same surgeon.
Nodal samples were fixed in formalin and embedded in
paraffin. All lymph nodes were sectioned at least one sec-
tion at 5 um thickness, and were separated for hematoxylin
and eosin (HE) staining. SLNs that were determined nega-
tive by conventional pathological methods were further
examined using cytokeratin (CK; monoclonal mouse anti-
cytokeratin AE1/AE3; Abcam,1:100) IHC to identify micro-
metastasis. Sentinel nodes were examined using at least
Table 1 Patient demographic and clinical data
Variables Statistics
Age (y) 57.00 ± 13.82
Lymph node ratio 0.05 ± 0.10
Survival duration (months) 61.69 ± 17.20

















Recurrence or metastasis 14 (25.9)
DFS, disease free survival; HE, hematoxylin-eosin; SLN, sentinel lymph node.
Continuous variables were shown as mean± standard deviation and
categorical variables were presented as number (%).
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node micrometastasis was defined by identification of one
or more CK-labeled positive cells in lymph nodes in which
metastases were not detected by HE staining in combin-
ation with histological and cell morphological findings. All
samples, including tumors, nodes, HE-stained, and IHC-
stained sections were evaluated separately by two experi-
enced pathologists. If different results were obtained, a
third pathologist reviewed the specimens and slides to
make the final determination.
SLNs and non-SLNs which were positive for micrometas-
tasis by HE staining were categorized as N+, negative
lymph nodes were categorized as N0, and SLNs with micro-
metastasis detected by IHC staining only were categorized
as N0(i+). All treatment decisions were based upon the
results of standard HE histopathological staging. Patients
with stage II and III disease were given fluorouracil-based
adjuvant chemotherapies.
Patient follow-up
All patients were followed-up through clinic visits.
Follow-up included clinical examination, carcinoembryo-
nic antigen (CEA) level, chest X-ray, and abdominal ultra-
sound every 3–6 months for 2 years, then every 6–
12 months. Patients with multiple polyps in the colon
received colonoscopies annually, and those with vessel
invasion or poor differentiation also received CT scans
annually.
Statistical analysis
Overall survival (OS) duration was calculated from the
date when a patient was enrolled in the study to the date
of death or last follow-up visit. Disease-free survival
(DFS) duration was defined as the interval between the
date of enrollment in the study and the date recurrence
or metastasis was identified.
Data were presented as mean ± standard deviation for
continuous variables and number (percentage) for cat-
egorical variables. Kaplan-Meier survival curves were
calculated, and the difference in survival statuses among
the three groups (N+, N0, and N0(i+)) was tested by the
Breslow estimation method. A Cox proportional hazard
model was used to determine the factors associated with
survival status, recurrence, and metastasis. Factors with
p< 0.1 revealed by univariate Cox proportional hazard
model analysis, age, and sex were then included in fur-
ther multiple analyses in order to establish the final
model. The forward stepwise method was applied when
establishing the multiple Cox proportional model. Statis-
tical significance was defined as p< 0.05. All statistical
analyses were performed using PASW software (version
18.0, IBM SPSS Inc., Chicago, IL).
In addition, detection rate, accuracy, sensitivity, and
false negative rate were reported for the examination ofSLN localization. These indexes were determined in ac-
cordance of following formulas [20]:
Detection rate (%): (number of patients with success-
fully retrieved SLNs/number of patients enrolled) × 100.
Sensitivity (%) of lymph node micrometastasis: (num-
ber of patients with positive SLNs/number of patients
with micrometastasis in any lymph node) × 100.
False-negative rate (%): 100 - sensitivity
Accuracy (%): (number of patients with correct nodal
status predicted/number of patients enrolled) × 100.
Lymph node ratio: (number of positive lymph nodes/
total number of lymph nodes) × 100.Results
Patients and clinical characteristics
A total of 54 patients between 25 and 82 years of age were
enrolled, including 32 males and 22 females. Patient
demographic and clinical data are shown in Table 1. More
than 80% of patients were stage T3 or above, about 86% of
patients were stage II or III, and approximately 90% of
patients had lesions grade II or above.
Table 3 IHC staining for micrometastasis in patients with




IHC, immunohistochemistry; HE, hematoxylin-eosin; SLN, sentinel lymph node.
*Patients with positive ICH staining, of whom 4 of 12 had HE-negative stained
lymph nodes and 8 had HE-negative stained SLNs but HE-positive stained
non-SLNs at primary HE staining.
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Sentinel lymph nodes were detected in all 54 patients.
There were 32 patients in whom no lymph node micro-
metastasis were detected by HE staining (N0) and 22
patients with positive lymph nodes micrometastasis
detected by HE staining (N+) in non-SLNs. In contrast
only 7 SLNs stained positive with HE (Table 2). Using
HE examination as the standard, the sensitivity, non-
detection rate, and accuracy rate of SLN micrometastasis
detection were 31.8% (7/22), 68.2% (15/22), and 72.2%
(32 + 7 = 39/54), respectively.
Further examination for lymph node micrometastasis
by ICH in patients who were HE(−) showed that 12 of
the 47 patients were positive for micrometastasis in
SLNs (Table 3). In those patients, 4 of 12 had non-SLNs
that were HE-negative (N0(i+)), and 8 patients had non-
SLNs that were HE-positive. The 4 patients who were
upstaged consisted of 2 stage I patients and 2 stage II
patients who were upstaged to stage III; thus the up-
staging rate was 12.5% (4/32 of non-SLN HE(−)
patients). Additionally, based on the assumption that the
results of micrometastasis detection could be a reference
in terms of stage, the accuracy rate was increased from
72.2% to 87% [(7 + 32 + 8)/54].
Survival analysis
Among the 54 patients, 4 patients with micrometastasis
detected in SLNs by IHC staining only were upstaged
(N0(i+), group A), 28 patients had negative HE and IHC
staining (N0, group B), and the other 22 patients had
positive HE staining (N+, group C). In groups A and B,
two patients in each group had metastatic disease and
died, and in group C, 10 had recurrent or metastatic dis-
ease and 9 died.
The Kaplan-Meier OS curve is shown in Figure 1. The
survival status of the three groups were significantly dif-
ferent (p = 0.003). Regardless of upstaging status, all
patients were alive 1 year after they participated in the
study. At the third and the fifth year, the OS of group A
was reduced to 75% and 50%, respectively; that of group
B also declined to 96.3% and 92.3%, respectively; and
that of group C were 90.5% and 53.5% respectively.
The Kaplan-Meier DFS curve is shown in Figure 2. In
group A, the 1- and 3-year DFS was 100% and 50%, re-
spectively, and no further change was noted. From 100%
at the first year, the DFS rate of group B decreased to
96.4% and 92.4% at 3- and 5-years, respectively. In groupTable 2 HE examination for micrometastasis in SLNs
(N= 54)
HE staining Non-SLN SLN
Positive (N+) 22 7
Negative (N0) 32 47
HE, hematoxylin-eosin; SLN, sentinel lymph node.C, the 1-year DFS rate was 86.1%, and decreased to
76.0% and 47.5% at 3- and 5-years, respectively. The
three groups had statistically different DFS status
(p = 0.001).
Cox proportional hazard model
The results of Cox proportional hazard model with re-
gard to survival are summarized in Table 4. The hazard
of death was increased as the lymph node ratio increased
(hazard ratio [HR] = 1.08, 95% confidence interval [CI]:
1.03-1.13, p = 0.003). Moreover, patients with an upstage
of N0(i+) (HR= 10.28, 95% CI: 1.44-73.34, p = 0.020) and
N+ (HR= 7.93, 95% CI: 1.71-36.83, p = 0.008) had a
higher hazard of death as compared with those with an
upstage of N0. In addition, patients with positive HE
staining were more likely to be dead (HR= 4.82, 95% CI:
1.48-15.70, p = 0.009). However, HE staining and lymph
node ratio were dropped in the multivariate model; only
the effect of upstaging was significant.
Similar results were found for recurrence or/and metas-
tasis (Table 5). In univariate analysis, significant factors
were lymph node ratio, upstaging, and positive HE stain-
ing; whereas, once again upstage was the only significantFigure 1 Kaplan-Meier curves of overall survival in 54 patients (n=3
in group N0(i+), n=28 in group N0, and n=22 in group N+).
Breslow estimation method was used to test differences in survival
among groups.
Figure 2 Kaplan-Meier curves of disease-free survival in 54
patients (n=3 in group N0(i+), n=28 in group N0, and n=22 in
group N+). Breslow estimation method was used to test differences
in disease-free survival among groups.
Table 4 Cox proportional hazard model for survival
status
Univariate Multivariate
Age (y) 0.99 (0.95-1.03) 0.99 (0.96-1.04)
Lymph node ratio† 1.08 (1.03-1.13)* -
Gender
Female Reference Reference
Male 2.49 (0.69-9.06) 1.16 (0.28-4.81)
Location of tumor
Colon Reference -
Rectum 1.06 (0.36-3.16) -
Depth of invasion
T1/T2 Reference Reference
T3 2.15 (0.46-10.12) 3.9 (0.62-24.42)
T4 0.70 (0.12-4.17) 0.76 (0.11-5.36)
Stage
I Reference -
II 0.81 (0.08-7.75) -
III 3.67 (0.47-29.00) -
Tumor grade
I Reference -
II 0.93 (0.12-7.31) -
III 0.81 (0.07-9.03) -
Upstage
N0(i+) 10.28 (1.44-73.34)* 20.32 (2.09-197.98)*
N0 Reference Reference
N+ 7.93 (1.71-36.83)* 10.06 (2.04-49.58)*
HE examination
Negative Reference -
Positive 4.82 (1.48-15.70)* -
SLN examination
Negative Reference -
Positive 1.50 (0.33-6.84) -
HE, hematoxylin-eosin; SLN, sentinel lymph node.
Dash denotes variables were not included in the final model.
* Indicates p< 0.05.
† Ratio values were multiplied by 100.
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and N+patients was 8.07 (95% CI: 1.09-59.50, p = 0.041)
and 7.87 (95% CI: 1.68-36.79, p = 0.009) times higher than
those with N0 disease.
Discussion
Lymph node metastasis is one of the key factors of poor
outcomes in patients with colorectal cancer. However,
recurrence and metastasis rates are high in stage II colo-
rectal cancer patients even without lymph node metasta-
sis, and it has been reported that stage IIB patients have
a poorer prognosis than stage III patients [11,21]. In-
accurate lymph node staging may be one of the reasons
for the low survival rate. Methods examined to improve
lymph node staging include increasing number of lymph
nodes for postoperative examination and using micro-
metastasis detection; however, it is difficult to apply
these techniques in clinical practice due to procedural
complexity and costs.
Theoretically, SLN detection can help reduce under-
staging because the SLN is the first to receive drainage
from the tumor. In our study, ex vivo SLN detection was
used in 54 patients and we found an identification rate
of 100% and 4 patients were upstaged. Our results are
consistent with other studies that have shown SLN map-
ping results in a higher detection rate and upstaging
when combined with immunohistochemical or RT-PCR
techniques [1,16,17,20,22]. A prospective randomized
study of SLN ultrastaging showed that SLNs were suc-
cessfully identified in 82 of 84 patients (97.6%), and sig-
nificant nodal upstaging occurred (38.7% to 57.3%,
p = 0.019) [22]. Another prospective multicenter trial
demonstrated that at least one SLN was identified in 268
of 315 enrolled patients (detection rate, 85%) and 21%(30 of 141) of the patients, classified as pN0 by routine
histopathological examination, were found to have
micrometastasis or isolated tumor cells in the SLN [20].
Interestingly, a study by Cheng et al. [28] of colorectal
cancer patients and liver metastases showed that nuclear
beta-catenin overexpression in metastatic lymph nodes
was strongly associated with liver metastasis. Perin et al.
[29] reported a case a 46-year-old female who under-
went sigmoid colon resection for colon cancer who sub-
sequently developed pathologically proven breast
metastasis of the colon malignancy. Examination of the
Table 5 Cox proportional hazard model for recurrence or/
and metastasis
Univariate Multiple
Age (y) 0.98 (0.95-1.02) 1.00 (0.97-1.04)
Lymph node ratio† 1.06 (1.02-1.11)* -
Gender
Female Reference Reference
Male 1.75 (0.55-5.58) 2.19 (0.59-8.20)
Location of tumor
Colon Reference -
Rectum 1.16 (0.40-3.30) -
Depth of invasion
T1 or T2 Reference -
T3 2.23 (0.47-10.51) -
T4 1.03 (0.19-5.63) -
Stage
I Reference -
II 0.83 (0.09-8.02) -
III 4.60 (0.59-36.07) -
Tumor grade
I Reference -
II 0.95 (0.12-7.41) -
III 0.69 (0.06-7.67) -
Upstage
N0(i+) 9.97 (1.40-71.07)* 8.07 (1.09-59.50)*
N0 Reference Reference
N+ 9.67 (2.10-44.47)* 7.87 (1.68-36.79)*
HE examination
Negative Reference -
Positive 5.93 (1.84-19.12)* -
SLN examination
Negative Reference -
Positive 1.11 (0.25-4.96) -
HE, hematoxylin-eosin; SLN, sentinel lymph node.
Dash denotes variables were not included in the final model.
* Indicates p< 0.05.
† Ratio values were multiplied by 100.
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colon primary.
Despite the encouraging results, there remains contro-
versy regarding false negative rates. Our false negative rate
was 68.2%, higher than that reported by other authors,
and our results indicated that the SLN did not predict
overall nodal status. This is similar to the findings of a re-
cent systematic review and meta-analysis performed by
van der Pas et al. [1]. The authors included 52 studies with
3767 SLN procedures (78.6% colon carcinoma, 21.4% rec-
tal carcinoma) and found a mean detection rate of 94%
and a pooled sensitivity of 76%. Retter et al. [30] reportedthe results of 31 patients who received surgery for colon
carcinoma in which in vivo SLN mapping was performed,
and found that although the SLN was identified in 28 of
the 31 patients, the false-negative rate to identify stage III
disease was 66% and the accuracy was 14%. Finan et al.
[31] also reported that ex vivo SLN mapping did not im-
prove staging after proctectomy for rectal cancer. In con-
trast, van Schaik et al. [4] reported no false negative SLNs
in 44 patients. The reasons for the high false-negative
rates in some studies are unclear, but may possibly include
the T stage, tumor location, and learning curve for SLN
mapping. Thus, we believe that the cumulative data indi-
cate that routine SLN detection alone cannot replace the
conventional method that examines all dissected lymph
nodes because a high false-negative rate tends to down-
grade tumor staging such that some patients who may
benefit from adjuvant chemotherapy will not receive it.
Although almost all studies analyzing SLN mapping for
colorectal cancer demonstrate the detection of microme-
tastasis, the clinical significance of lymph node microme-
tastasis, particularly that identified solely by IHC staining,
is unknown. There have been extensive studies on lymph
node micrometastasis using IHC or RT-PCR techniques,
and some reports have indicated that micrometastasis de-
tection by ICH was associated with poor prognosis of
colon cancers [8-10]. However, other studies have
reported conflicting findings [5,11]. Dahl et al. [18]
reported that only patients with metastatic lymph nodes
detected directly or within a SLN died of metastatic dis-
ease. Saha et al. [19] demonstrated with a 2-year mini-
mum follow-up of 153 patients who underwent SLN
mapping, 7% had recurrences as compared with 25% of
162 patients with standard resection and nodal staging.
Bilchik et al. [27] reported that no colon cancer patient
with a negative SLN by HE and PCR had a recurrence at a
mean follow-up of 25 months. Our results indicated that
patients without lymph node metastasis by HE staining
who are upstaged by ICH detection of micrometastasis
have a significantly poorer OS and DFS. However, survival
analysis showed no difference in OS and DFS between the
stage III and stage N0(i+) groups. This may imply that
patients with SLN micrometastasis have the same progno-
sis as patients with stage III disease, which suggests that
focusing on the detection of SLN micrometastasis could
become a useful factor in determining prognosis, although
further study is warranted due to limited number of cases.
In addition, in multivariate analysis upstaging by SLN
micrometastasis identification was not an independent
prognostic factor; the small number of study patients may
be the reason.
The primary limitation of the study is the relatively
small number of patients. However, the results do sup-
port those of other studies of the utility of SLN mapping
and IHC detection of micrometastasis.
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Our findings indicate that SLN detection is feasible for
colorectal cancers, and ex vivo localization and micro-
metastasis detection of SLNs in colorectal cancers can
upgrade tumor staging. Though SNL examination in
combination with IHC for the detection of micrometas-
tasis can reduce the false-negative rate, the method is
not suggested to replace the conventional N-staging
method that examines all dissected lymph nodes. More-
over, ex vivo localization and micrometastasis detection
of SLNs in colorectal cancers may become a factor
affecting prognosis and guiding treatment.Competing interests
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